The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myeloma

  The European Commission has approved marketing authorisation (e.g. a license) for melphalan flufenamide (also called melflufen), a drug marketed in Europe by Oncopeptides with the name of Pepaxti®. This follows the previous positive recommendation from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).

Meet Lise-Lott Eriksson, president of Myeloma Patients Europe (MPE)

Since 2015 Lise-Lott has been Chairman of the Swedish Blood Cancer Association, previously Chairman of the Blood Cancer Society in Stockholm and now the president of Myeloma Patients Europe (MPE). Lise-Lott is very active in policy-related issues within the Swedish cancer care area. She focuses on access to new drugs for haematological disorders (especially myeloma), reimbursement, pricing, patient influence in clinical trials and health technology assessment decisions. She works actively to raise the status of…